VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and head of the Familial Cancer Centre at The Royal Melbourne Hospital, Australia. He discussed the clinical potential of BCL-2 modulation with Oncology Times reporter Sarah Maxwell.
You may also like...
Pelvic Radiotherapy Brought No Benefit in High-Risk Localized Prostate Cancer: GETUG 12 Trial 9 May, 2015 COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey 28 May, 2020 ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow 3 Jun, 2006 ASCO Audio Journal of Oncology – August 1st 2006 30 Jul, 2006
- Previous story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Next story Targeting Bone Microenvironment in Breast Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014